Approved biosimilar ranibizumab—a global update

Efficacy and Safety of a Proposed Ranibizumab Biosimilar Product vs a Reference Ranibizumab Product for Patients With Neovascular Age-Related Macular Degeneration

Se Joon Woo, Miroslav Veith, Jan Hamouz et al. · JAMA Ophthalmology · 2020 · 81 citations · Full text

Medicine, Ophthalmology, Pharmacology +15

Efficacy and Safety of Biosimilar FYB201 Compared with Ranibizumab in Neovascular Age-Related Macular Degeneration

Frank G. Holz, Piotr Oleksy, Federico Ricci et al. · Ophthalmology · 2021 · 67 citations · Full text

Medicine, Ophthalmology, Pharmacotherapy +17

Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase III randomised clinical trial outcomes

Neil M. Bressler, Miroslav Veith, Jan Hamouz et al. · British Journal of Ophthalmology · 2021 · 44 citations · Full text

Medicine, Ophthalmology, Pharmacology +16

A prospective, randomized, parallel group, double blind, multicenter study to compare the efficacy, safety and immunogenicity of Lupin’s Ranibizumab with Lucentis® in patients with neovascular age-related macular degeneration

Ramandeep Singh, Rohan Chauhan, Ashish Saxena et al. · Indian Journal of Ophthalmology · 2022 · 22 citations · Full text

Medicine, Ophthalmology, Pharmacotherapy +15

Randomised, Double-blind, Comparative Clinical Study of New Ranibizumab Biosimilar in Neovascular (Wet) Age-Related Macular Degeneration

Prasad Apsangikar, Pravin Ghadge, Manoj Naik et al. · Clinical ophthalmology · 2021 · 21 citations · Full text

Medicine, Ophthalmology, Pharmacotherapy +17